Dapagliflozin: Early HF Treatment Accelerates Recovery

A significant pooled analysis presented at the American College of Cardiology (ACC) Scientific Session on March 30 supports the early initiation of dapagliflozin for patients experiencing acute heart failure. This comprehensive analysis, which incorporated data from over 3,500 patients across major trials, indicates that starting dapagliflozin during hospitalization can expedite decongestion and decrease adverse heart failure events, all while maintaining a favorable safety profile.

Further mechanistic investigations suggest that dapagliflozin offers benefits beyond simply removing excess fluid. These include improvements in coronary microvascular dysfunction and a reduction in local cardiac inflammation. The findings advocate for incorporating dapagliflozin into standard inpatient heart failure treatment protocols, rather than waiting until a patient is discharged.

The rising incidence of acute heart failure presents a substantial financial strain on global healthcare systems due to the high costs associated with hospitalizations and frequent readmissions. Experts anticipate a significant increase in hospitalised patients, potentially more than doubling in the future, highlighting the urgent need for more effective treatment strategies.